Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3.

Article  PubMed  Google Scholar 

Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens VEPP, Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108–18. https://doi.org/10.1016/j.ejca.2021.11.023.

Article  PubMed  Google Scholar 

Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: a comprehensive overview. J Egypt Natl Canc Inst. 2020;32(1):5. https://doi.org/10.1186/s43046-020-0016-x.

Article  PubMed  Google Scholar 

Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3(Suppl 3):S206–14. https://doi.org/10.1016/S1590-8658(10)60507-5.

Article  PubMed  Google Scholar 

Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect. 2015;21(11):969–74. https://doi.org/10.1016/j.cmi.2015.06.026.

Article  CAS  PubMed  Google Scholar 

Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, Azizi G. Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol. 2022;111: 109130. https://doi.org/10.1016/j.intimp.2022.109130.

Article  CAS  PubMed  Google Scholar 

El-senosy FM, Morsy MM, El-Tokhy HM, ElBagour I, Elhadad SM. Evaluation of serum level of IL-6 in chronic hepatitis C virus infected egyptian patients. Am J Med Sci Medicine. 2018;6(1):5–12. https://doi.org/10.12691/ajmsm-6-1-2.

Article  CAS  Google Scholar 

Gao B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol. 2012;27 Suppl 2(Suppl 2):89–93. https://doi.org/10.1111/j.1440-1746.2011.07003.x.

Article  CAS  PubMed  Google Scholar 

Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, Wörns MA. Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. Aliment Pharmacol Ther. 2019;50(10):1112–9. https://doi.org/10.1111/apt.15515.

Article  CAS  PubMed  Google Scholar 

Adnan F, Khan NU, Iqbal A, Ali I, Petruzziello A, Sabatino R, Guzzo A, Loquercio G, Botti G, Khan S, Naeem M, Khan MI. Interleukin-6 polymorphisms in HCC patients chronically infected with HCV. Infect Agent Cancer. 2020;15:21. https://doi.org/10.1186/s13027-020-00285-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elsaid A, Abdel-Aziz AF, Elmougy R, Elwaseef AM. Association of polymorphisms G(-174)C in IL-6 gene and G(-1082)A in IL-10 gene with traditional cardiovascular risk factors in patients with coronary artery disease. Indian J Biochem Biophys. 2014;51(4):282–92.

CAS  PubMed  Google Scholar 

Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol. 2013;19(16):2449–55. https://doi.org/10.3748/wjg.v19.i16.2449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park BL, Lee HS, Kim YJ, Kim JY, Jung JH, Kim LH, Shin HD. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med. 2003;35(2):76–82. https://doi.org/10.1038/emm.2003.11.

Article  CAS  PubMed  Google Scholar 

Olomolaiye O, Wood NA, Bidwell JL. A novel NlaIII polymorphism in the human IL-6 promoter. Eur J Immunogenet. 1998;25(2–3):267.

CAS  PubMed  Google Scholar 

Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis International Ascites Club. Hepatology. 1996;23(1):164–76. https://doi.org/10.1002/hep.510230122.

Article  CAS  PubMed  Google Scholar 

Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91. https://doi.org/10.3758/bf03193146.

Article  PubMed  Google Scholar 

Ntellas P, Chau I. Updates on systemic therapy for hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2024;44:e430028. https://doi.org/10.1200/EDBK_430028. American Society of Clinical Oncology. Annual Meeting.

Article  PubMed  Google Scholar 

Dai CY, Tsai YS, Chou WW, Liu T, Huang CF, Wang SC, Tsai PC, Yeh ML, Hsieh MY, Huang CI, Vanson Liu SY, Huang JF, Chuang WL, Yu ML. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. Oncotarget. 2018;9(13):11291–302. https://doi.org/10.18632/oncotarget.24129.

Article  PubMed  PubMed Central  Google Scholar 

Shao YY, Lin H, Li YS, Lee YH, Chen HM, Cheng AL, Hsu CH. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2017;47(10):949–53. https://doi.org/10.1093/jjco/hyx103.

Article  PubMed  Google Scholar 

Song J, Zhang X, Ge Q, Yuan C, Chu L, Liang HF, Liao Z, Liu Q, Zhang Z, Zhang B. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. J Cell Biochem. 2018;119(10):8419–31. https://doi.org/10.1002/jcb.27050.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Lin H, Wu G, Zhu M, Li M. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol. 2021;11:760971. https://doi.org/10.3389/fonc.2021.760971.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, Ahmadian MR, Moll JM, Scheller J. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 2018;293(18):6762–75. https://doi.org/10.1074/jbc.RA117.001163.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prenissl N, Lokau J, Rose-John S, Haybaeck J, Garbers C. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage. Cytokine. 2019;114:1–5. https://doi.org/10.1016/j.cyto.2018.11.023.

Article  CAS  PubMed  Google Scholar 

Rose-John S. Interleukin-6 Family Cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415. https://doi.org/10.1101/cshperspect.a028415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sghaier I, Mouelhi L, Rabia NA, Alsaleh BR, Ghazoueni E, Almawi WY, Loueslati BY. Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine. 2017;89:62–7. https://doi.org/10.1016/j.cyto.2016.10.004.

Article  CAS  PubMed  Google Scholar 

Dondeti MF, El-Maadawy EA, Talaat RM. Hepatitis-related hepatocellular carcinoma: insights into cytokine gene polymorphisms. World J Gastroenterol. 2016;22(30):6800–16. https://doi.org/10.3748/wjg.v22.i30.6800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Yan Z, Ye Q. Interleukin-6 gene polymorphisms and susceptibility to liver diseases: a meta-analysis. Medicine. 2019;98(50):e18408. https://doi.org/10.1097/MD.0000000000018408.